Clonal ZEB1-driven mesenchymal transition promotes targetable oncologic anti-angiogenic therapy resistance

Glioblastoma responses to bevacizumab are invariably transient with acquired resistance. We profiled paired patient specimens and bevacizumab-resistant xenograft models pre- and post-resistance towards the primary goal of identifying regulators whose targeting could prolong the therapeutic window, a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Chandra, Ankush, Jahangiri, Arman, Chen, William, Nguyen, Alan T., Yagnik, Garima, Pereira, Matheus P., Jain, Saket, Garcia, Joseph H., Shah, Sumedh S., Wadhwa, Harsh, Joshi, Rushikesh S., Weiss, Jacob, Wolf, Kayla J., Lin, Jung-Ming G., Müller, Sören, Rick, Jonathan W., Diaz, Aaron A., Gilbert, Luke A., Kumar, Sanjay, Aghi, Manish K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236890/
https://ncbi.nlm.nih.gov/pubmed/32041837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-1305
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados